Skip to Content

Iovance Biotherapeutics, Inc. 

Securities Class Action

  • Date:
  • 10/9/2020
  • Company Name:
  • Iovance Biotherapeutics, Inc.
  • Stock Symbol:
  • IOVA
  • Status:
  • Investigating

Case Finder

Locate any case using the tools below.

Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) on behalf of Iovance stockholders. Our investigation concerns whether Iovance has violated the federal securities laws and/or engaged in other unlawful business practices.
 

On October 5, 2020, Iovance issued a press release “provid[ing] a regulatory update for its tumor-infiltrating lymphocyte (TIL) therapy lifileucel in metastatic melanoma.”  Specifically, Iovance advised investors that “the Company and the [U.S. Food and Drug Administration] have not been able to agree on the required potency assays to fully define its TIL therapy, which is required as part of a BLA [Biologics License Application] submission.  The Company is continuing to refine the information from its current potency assays and simultaneously developing additional assays. As a result of these developments, the BLA submission is not expected by the end of 2020.”
 

On this news, Iovance’s stock price fell $3.96 per share, or 12.35%, to close at $28.10 per share on October 6, 2020.
 

If you purchased or otherwise acquired Iovance shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker, Melissa Fortunato, or Marion Passmore by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.

The individual or institution below (“Plaintiff”) has reviewed and agrees to the Bragar Eagel & Squire, P.C. (“BESPC”) retainer agreement and authorizes BESPC to prosecute an action on Plaintiff’s behalf under the federal securities laws or applicable state laws to recover damages on behalf of investors in Iovance Biotherapeutics. BESPC will prosecute the action on a full contingency basis and will forward all costs and expenses.
 

Case Finder

Locate any case using the tools below.

You may share a link to this page on any of the sites listed below or send link via email: